CSPC Pharmaceutical Group's (HKG:1093) Sirolimus for Injection has been granted breakthrough therapy designation by China's National Medical Products Administration for the intended indication of monotherapy for malignant perivascular epithelioid cell tumor, a Feb. 28 bourse filing said.
The oral formulation of sirolimus previously approved for marketing is primarily indicated for the prevention of organ rejection in kidney transplant patients.
Sirolimus is currently undergoing multiple phase II and III clinical studies in China for the treatment of solid and hematological tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.